Price T Rowe Associates Inc Akebia Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 137,905 shares of AKBA stock, worth $262,019. This represents 0.0% of its overall portfolio holdings.
Number of Shares
137,905
Previous 126,648
8.89%
Holding current value
$262,019
Previous $168,000
56.55%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding AKBA
# of Institutions
128Shares Held
63.3MCall Options Held
50.6KPut Options Held
203K-
Black Rock Inc. New York, NY11.6MShares$22.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$20.7 Million0.0% of portfolio
-
State Street Corp Boston, MA6.3MShares$12 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.9 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA4.8MShares$9.11 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $349M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...